UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 7, 2016
CORVUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-37719 |
|
46-4670809 |
|
(State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
863 Mitten Road, Suite 102
Burlingame, CA 94010
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (650) 900-4520
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 7, 2016, the Board of Directors (the “Board”) of Corvus Pharmaceuticals, Inc. (“Corvus” or the “Company”), approved, on recommendation of the Compensation Committee of the Board, increases to the 2017 annual salaries for each of the Company’s Chief Financial Officer, Vice President, Pharmaceutical Development, and Vice President, Chemistry Research, as well as new stock awards for such executive officers and the Company’s Chief Executive Officer. The stock option awards to each of the executive officers will be granted effective as of the close of business on December 7, 2016 with an exercise price equal to the closing price of the Company’s common stock as reported on The NASDAQ Global Market on the date of grant. The awards will be made pursuant to the Company’s 2016 Equity Incentive Award Plan and will vest in equal monthly installments over 48 months, subject to continued service as of each vesting date.
The following table sets forth the 2017 annual salaries and number of shares underlying the stock option awards for each of the named executive officers and principal financial officer:
|
Name and Principal Position |
|
2017 Salary |
|
Stock Option Award |
| |
|
Richard A. Miller, M.D. |
|
$ |
300,000 |
|
160,000 |
|
|
Chief Executive Officer |
|
|
|
|
| |
|
Leiv Lea |
|
$ |
291,500 |
|
25,000 |
|
|
Chief Financial Officer |
|
|
|
|
| |
|
William B. Jones, Ph.D. |
|
$ |
265,000 |
|
25,000 |
|
|
Vice President, Pharmaceutical Development |
|
|
|
|
| |
|
Erik J. Verner, Ph.D. |
|
$ |
250,000 |
|
25,000 |
|
|
Vice President, Chemistry Research |
|
|
|
|
| |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
CORVUS PHARMACEUTICALS, INC. | |
|
|
| |
|
Date: December 8, 2016 |
By: |
/s/ Leiv Lea |
|
|
|
Leiv Lea |
|
|
|
Chief Financial Officer |